No Muscle Depletion with High Visceral Fat as a Novel Beneficial Biomarker of Sorafenib for Hepatocellular Carcinoma

BACKGROUND: Sorafenib is a standard therapy for patients with advanced hepatocellular carcinoma (HCC). However, no predictive biomarkers of sorafenib efficacy have been discovered. Herein, we investigated the impact of body composition, such as skeletal muscle and visceral fat, on the prognosis of a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Liver Cancer
Main Authors: Saeki, Issei, Yamasaki, Takahiro, Maeda, Masaki, Kawano, Reo, Hisanaga, Takuro, Iwamoto, Takuya, Matsumoto, Toshihiko, Hidaka, Isao, Ishikawa, Tsuyoshi, Takami, Taro, Sakaida, Isao
Formato: Artigo
Idioma:Inglês
Publicado em: S. Karger AG 2018
Assuntos:
Original Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6249591/
https://ncbi.nlm.nih.gov/pubmed/30488024
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000487858
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados